On the evening of November 25th, Dezhan Health announced that the largest shareholder of the company, Shanghai Yueye Equity Investment Management Partnership Enterprise (Limited Partnership) (hereinafter referred to as "Shanghai Yueye"), has recently been ruled by the Shanghai Third Intermediate People's Court to confirm its liquidation plan. All shares held by Shanghai Yueye in the company will be liquidated and disposed of through public auction.

According to the data, Shanghai Yueye holds 414 million shares of the company's unrestricted tradable shares, accounting for 19.13% of the company's total share capital and 19.37% of the total share capital after excluding the number of shares in the company's repurchase special account. There is no pledge or freezing of the shares it holds.

The announcement states that the auction matters involved in this liquidation plan have not yet officially begun to be implemented. The specific arrangements and related requirements for public auctions shall be subject to the announcement information displayed on the judicial auction website of Shanghai Third Intermediate People's Court.

It is worth noting that Dezhan Health also reminded investors in the announcement that Shanghai Yueye is not the controlling shareholder of the company, and its liquidation will not result in a change of control of the company, nor will it have a significant impact on the company's governance structure and ongoing operations.

According to the data, the actual controller of Dezhan Health is the Xinjiang State owned Assets Supervision and Administration Commission, and Xinjiang Jintou and its wholly-owned subsidiaries Xinjiang Kaidi Investment and Xinjiang Kaidi Mining are concerted action persons. The three jointly hold 24.79% of the shares of Dezhan Health, exceeding the 19.13% held by the largest shareholder Shanghai Yueye. Xinjiang Jintou is a company directly supervised by the Xinjiang State owned Assets Supervision and Administration Commission. According to shareholder information, the Xinjiang State owned Assets Supervision and Administration Commission holds 95.86804% of the shares, while the Autonomous Region Department of Finance holds 4.13196%.

Recently, several shareholders of listed companies have had their shares auctioned off by the judiciary, but more of them have been interpreted as positive by the market, bringing infinite imagination to the market.

For example, in * ST Tongzhou, Mr. Yuan Ming, a shareholder of the company, held 123 million shares of the company's stock (accounting for 16.50% of the total share capital) that were auctioned off by the judiciary and successfully sold on October 22nd* Since August, ST Tongzhou's stock price has cumulatively increased by over 260%. Dongfang Group is also a shareholder (Xizang Dongfang Runlan Industry) whose shares were auctioned off. The company's share price once rose for eight consecutive trading limits in October, with the range share price rising by more than 110%. Companies such as Yitong Century, Huayang Lianzhong, and Derun Electronics have all had their shareholder shares auctioned off, but it has had little impact on listed companies, and their stock prices have steadily risen.

Industry insiders point out that listed companies are generally models of corporate governance in China. Although shareholder shareholding auctions have an impact on company operations, as public companies, due to a sound corporate governance system, changes in a single shareholder will not have a significant impact on listed companies.

In addition, the withdrawal of shareholders with weak background strength or even operational risks may also be beneficial for listed companies. On the one hand, new shareholders can be introduced to optimize the company's equity structure; On the other hand, the entry of new shareholders may bring new opportunities for the company in terms of business or capital, which is even more of an opportunity for listed companies. Because of this, the individual stocks held by multiple shareholders and auctioned off can only lead to a subsequent surge in stock prices.

From a business perspective, Dezhan Health's various businesses are progressing smoothly. In the field of cardiovascular and cerebrovascular chronic diseases, the company's two core products for lipid-lowering drugs, "Ale" and "Nile," have seen steady growth in sales. The company is also exploring the potential of existing products such as warfarin sodium tablets and trimetazidine hydrochloride tablets, among which warfarin sodium tablets completed their first sales and shipment in June this year. The two innovative cardiovascular and cerebrovascular drugs under research have made significant progress. The WYY project, an innovative neuroprotective agent for the brain, has completed its preliminary research and will begin the preparation of toxicology batches and clinical test samples according to plan; The ZT project for antithrombotic drugs is currently undergoing the synthesis of better candidate compounds and further activity evaluation.

In the field of health business, among the two key projects of its subsidiary Hanpeptide Biotechnology, the Simeglutide project has completed the construction of engineering strains and established an original seed bank; The recombinant collagen project has developed type I, III, and XVII humanized collagen proteins, and the recombinant type III humanized collagen protein has completed three batches of pilot production.

In other fields, the pharmaceutical research of a new drug project for the treatment of pulmonary arterial hypertension with cannabidiol (CBD) is nearing completion. The Hainan Decheng International Medical and Health Care Complex project is currently under construction, positioned as an international medical and health care complex.